^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    intismeran autogene (mRNA-4157)

    i
    Other names: mRNA-4157, mRNA 4157, V940, mRNA4157, V 940, V-940
    Associations

    News

    Trials
    Company:
    Merck (MSD), Moderna
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3d
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; Business reasons
    Trial termination
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    12d
    INTerpath-001: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) (clinicaltrials.gov)
    P3, N=1089, Active, not recruiting, Merck Sharp & Dohme LLC | N=625 --> 1089
    Enrollment change
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    21d
    Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy. (PubMed, Front Immunol)
    Clinical data reflects this, with the mRNA vaccine mRNA-4157 (KEYNOTE-942) demonstrating a significant recurrence-free survival (RFS) benefit in the adjuvant setting...This reflects the logistical and biological complexities inherent in developing personalised vaccines, highlighting challenges in both manufacturing and subject recruitment. These remain key obstacles impeding the widespread clinical application of such vaccines.
    Review • Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    TMB-H
    |
    intismeran autogene (mRNA-4157)
    28d
    INTerpath-13: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | N=59 --> 180
    Enrollment change • Trial initiation date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    1m
    INTerpath-014: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) (clinicaltrials.gov)
    P3, N=876, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1m
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=59, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    1m
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | N=49 --> 180
    Enrollment change • Trial initiation date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    1m
    INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=49, Recruiting, Merck Sharp & Dohme LLC | N=15 --> 49
    New P2 trial • Enrollment change
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    2ms
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    2ms
    A clinical study of V940 in people with non-small cell lung cancer (V940-013) (2025-520902-37-00)
    P1/2, N=15, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    2ms
    KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=161, Active, not recruiting, ModernaTX, Inc. | N=242 --> 161 | Trial completion date: Aug 2027 --> Nov 2027 | Trial primary completion date: Aug 2027 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    2ms
    Nanovaccines in Cancer Immunotherapy: Lymph Node-Targeted Strategies and Mechanistic Insights. (PubMed, Curr Pharm Des)
    Nanovaccine platforms can potentially overcome some constraints of conventional vaccines by enhancing lymph node targeting, antigen stability, and immunogenicity. Further research in this field could further advance targeted cancer immunotherapy.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    BNT111 • intismeran autogene (mRNA-4157)